

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number
WO 2004/007537 A3

(51) International Patent Classification⁷: **C12N 15/86**,
C07K 14/075, C12N 7/04, A61K 48/00

(FR). **LEGRAND, Valérie** [FR/FR]; 7, rue du Jet d'Eau,
F-67400 Illkirch Graffenstaden (FR).

(21) International Application Number:
PCT/IB2003/003336

(74) Agents: **MARTIN, Jean-Jacques** et al.; Cabinet Regim-
beau, 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR).

(22) International Filing Date: 10 July 2003 (10.07.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02360204.8 10 July 2002 (10.07.2002) EP
60/409,228 10 September 2002 (10.09.2002) US

(71) Applicant (*for all designated States except US*): **TRANS-
GENE S.A.** [FR/FR]; 11, rue de Molsheim, F-67000 Stras-
bourg (FR).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **ROSA-CALA-
TRAVA, Manuel** [FR/FR]; 15, rue du Neufeld, F-67100
Strasbourg (FR). **LEISSNER, Philippe** [FR/FR]; 5D,
avenue du Général de Gaulle, F-69300 Caluire et Cuire

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) *for US only*

[Continued on next page]

(54) Title: MODIFIED ADENOVIRAL FIBER WITH ABLATED TO CELLULAR RECEPTORS



Competitor soluble Heparin (30 µg/ml)

(57) Abstract: The present invention concerns a modified adenoviral fiber containing at least one mutation affecting one or more amino acid residue(s) of said adenoviral fiber interacting with at least one glycosaminoglycan and/or sialic acid-containing cellular receptor, as well as a trimer of such a modified adenoviral fiber. The present invention also relates to a DNA fragment, an expression vector encoding said modified adenoviral fiber. The present invention also concerns an adenoviral particle lacking a wild-type fiber and comprising the trimer of modified adenoviral fibers as well as a process for producing such an adenoviral particle. The present invention also provides a composition comprising such an adenoviral particle and the therapeutic use thereof.



Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(88) Date of publication of the international search report:

11 March 2004

INTERNATIONAL SEARCH REPORT

Internal Application No
PCT/IB 03/03336

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/86 C07K14/075 C12N7/04 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>LEISSNER P ET AL: "Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism"</p> <p>GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 8, no. 1, 2001, pages 49-57, XP002247417</p> <p>ISSN: 0969-7128</p> <p>the whole document</p> <p style="text-align: center;">--- -/--</p>	<p>1-7, 10-12, 15, 19-26, 29,30, 35,40,42</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

8 December 2003

Date of mailing of the international search report

02/01/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Chambonnet, F

INTERNATIONAL SEARCH REPORT

Internationa plication No
PCT/IB 03/03336

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EINFELD DA, SCHROEDER R, ROELVINK PW, LIZONOVA A, KING CR, KOVESDI I, WICKHAM TJ.: "Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions." JVIROL, vol. 75, no. 23, December 2001 (2001-12), pages 11284-11291, XP002264247 the whole document	1-5, 10-12
A	--- DECHECCHI MC, MELOTTI P, BONIZZATO A, SANTACATTERINA M, CHILOSI M, CABRINI G.: "Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5." J VIROL, vol. 75, no. 18, September 2001 (2001-09), pages 8772-8780, XP002264248 the whole document	1
A	--- DECHECCHI M C ET AL: "Heparan Sulfate Glycosaminoglycans Are Involved in Adenovirus Type 5 and 2-Host Cell Interactions" VIROLOGY, ACADEMIC PRESS, ORLANDO, US, vol. 268, no. 2, 15 March 2000 (2000-03-15), pages 382-390, XP004436082 ISSN: 0042-6822 the whole document	1
A	--- VAN RAAIJ M J ET AL: "Structure of the Human Adenovirus Serotype 2 Fiber Head Domain at 1.5 A Resolution" VIROLOGY, ACADEMIC PRESS, ORLANDO, US, vol. 262, no. 2, 30 September 1999 (1999-09-30), pages 333-343, XP004439798 ISSN: 0042-6822 page 386, column 2, paragraph 2 -page 387, column 1, paragraph 2	1-13
A	--- JAKUBCZAK JL, ROLLENCE ML, STEWART DA, JAFARI JD, VON SEGGERN DJ, NEMEROW GR, STEVENSON SC, HALLENBECK: "Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells." JOURNAL OF VIROLOGY, vol. 75, no. 6, March 2001 (2001-03), pages 2972-2981, XP002264249 the whole document	1, 12
	--- -/--	

INTERNATIONAL SEARCH REPORT

Internationa l Application No
PCT/IB 03/03336

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KIRBY I ET AL: "IDENTIFICATION OF CONTACT RESIDUES AND DEFINITION OF THE CAR-BINDING SITE OF ADENOVIRUS TYPE 5 FIBER PROTEIN" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 6, March 2000 (2000-03), pages 2804-2813, XP000985401 ISSN: 0022-538X the whole document ----	1
A	KIRBY I ET AL: "MUTATIONS IN THE DG LOOP OF ADENOVIRUS TYPE 5 FIBER KNOB PROTEIN ABOLISH HIGH-AFFINITY BINDING TO ITS CELLULAR RECEPTOR CAR" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 73, no. 11, November 1999 (1999-11), pages 9508-9514, XP000984778 ISSN: 0022-538X the whole document ----	1
P,A	LEGRAND VALERIE; LEISSNER PHILIPPE; WINTER AREND; MEHTALI MAJID; LUSKY MONIKA: "Transductional targeting with recombinant adenovirus vectors" CURRENT GENE THERAPY, vol. 2, no. 3, September 2002 (2002-09), pages 323-339, XP000117415 page 329, column 2, paragraph 2.3 ----	1
P,A	WO 02 096939 A (TRANSGENE SA) 5 December 2002 (2002-12-05) the whole document ----	21-43
T	WO 03 062400 A (NOVARTIS AG ; SCRIPPS RESEARCH INST (US); STEVENSON SUSAN C (US); KALE) 31 July 2003 (2003-07-31) the whole document -----	1

INTERNATIONAL SEARCH REPORT

Internationa plication No
PCT/IB 03/03336

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 02096939	A	05-12-2002	WO	02096939 A2	05-12-2002
			US	2003108521 A1	12-06-2003
WO 03062400	A	31-07-2003	WO	03062400 A2	31-07-2003
			US	2003215948 A1	20-11-2003